VALGANCICLOVIR FOR THE PROPHYLAXIS OF CYTOMEGALOVIRUS DISEASE IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS
- 1 May 2004
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 77 (9) , 1480
- https://doi.org/10.1097/01.tp.0000123081.81022.33
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- INFECTIOUS COMPLICATIONS OF SOLID ORGAN TRANSPLANTATIONSInfectious Disease Clinics of North America, 2001
- Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2000
- Single‐Dose Pharmacokinetics of Valganciclovir in HIV‐ and CMV‐Seropositive SubjectsThe Journal of Clinical Pharmacology, 1999
- Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive VolunteersClinical Pharmacokinetics, 1999